TABLE 3.
Summary of two‐way ANOVA analysis to test the effect of schizophrenia, cannabis use disorder and the potential interaction between both in ECs and other lipid mediators levels
| EC | Source of variation | DF | F | p |
|---|---|---|---|---|
| AEA | Schizophrenia | 1 | 1.800 | 0.1825 |
| Cannabis use disorder | 1 | 6.301 | 0.0136 * | |
| Interaction | 1 | 5.543 | 0.0204 * | |
| Residual | 107 | |||
| 2‐AG | Schizophrenia | 1 | 0.7552 | 0.3868 |
| Cannabis use disorder | 1 | 1.156 | 0.2848 | |
| Interaction | 1 | 0.2753 | 0.6009 | |
| Residual | 105 | |||
| 1‐AG | Schizophrenia | 1 | 0.6946 | 0.4065 |
| Cannabis use disorder | 1 | 0.4232 | 0.5168 | |
| Interaction | 1 | 0.2315 | 0.6314 | |
| Residual | 106 | |||
| PEA | Schizophrenia | 1 | 14.63 | 0.0002 * |
| Cannabis use disorder | 1 | 34.62 | <0.0001 * | |
| Interaction | 1 | 5.681 | 0.0189 * | |
| Residual | 107 | |||
| DEA | Schizophrenia | 1 | 0.4510 | 0.5034 |
| Cannabis use disorder | 1 | 9.007 | 0.0034 * | |
| Interaction | 1 | 4.435 | 0.0377 * | |
| Residual | 102 | |||
| OEA | Schizophrenia | 1 | 22.32 | <0.0001 * |
| Cannabis use disorder | 1 | 3.457 | 0.0657 | |
| Interaction | 1 | 8.026 | 0.0055 * | |
| Residual | 108 | |||
| LEA | Schizophrenia | 1 | 0.8670 | 0.3539 |
| Cannabis use disorder | 1 | 6.311 | 0.0135 * | |
| Interaction | 1 | 1.486 | 0.2256 | |
| Residual | 106 | |||
| NADA | Schizophrenia | 1 | 2.591 | 0.1105 |
| Cannabis use disorder | 1 | 5.157 | 0.0252 * | |
| Interaction | 1 | 2.724 | 0.1018 | |
| Residual | 106 |
Note: Significant p values (*p < 0.05) are shown in bold.